{"url":"https://newsforagent.com/news/2026-11-17/dewpoint-dptx8743-cancer-research-uk-trial","markdown_url":"https://newsforagent.com/news/2026-11-17/dewpoint-dptx8743-cancer-research-uk-trial.md","title":"Dewpoint Therapeutics Wins Cancer Research UK Trial Funding","headline":"Dewpoint Therapeutics' DPTX8743 to Enter Phase 1/2a Trial Funded by Cancer Research UK","description":"Cancer Research UK will fund and run a first-in-human Phase 1/2a trial of Dewpoint Therapeutics' MYC condensate modulator DPTX8743.","section":"Partnerships","published_at":"2026-11-17T08:40:00+00:00","modified_at":"2026-11-17T08:40:00+00:00","author":"News Desk","key_takeaways":["Cancer Research UK's Centre for Drug Development will fund, sponsor and execute CTA-enabling studies and a Phase 1/2a trial of DPTX8743.","Dewpoint Therapeutics retains all rights to DPTX8743 and may license the results and intellectual property.","Cancer Research UK is eligible for downstream milestones and royalties, with no amounts or specific milestones disclosed.","Dewpoint selected its first MYC condensate modulator development candidate in February 2026."],"companies":[{"name":"Dewpoint Therapeutics","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00004aa/dewpoint-therapeutics","website":"https://dewpointx.com"},{"name":"Cancer Research UK","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0005huh/cancer-research-uk","website":"http://www.cancerresearchuk.org"}],"source":{"publisher":"TradingView","title":"Dewpoint Therapeutics Advances DPTX8743 to a Funded Phase 1/2a Trial","url":"https://www.tradingview.com/news/tradingview:f46c0b0be9163:0-dewpoint-therapeutics-advances-dptx8743-to-a-funded-phase-1-2a-trial/"},"other_sources":[{"publisher":"PR Newswire","url":"https://www.prnewswire.com/news-releases/namsa-and-advanced-medical-solutions-announce-preferred-partnership-302932400.html"},{"publisher":"FinancialContent Business Page","url":"https://www.financialcontent.com/article/gnwcq-2026-11-12-istios-health-expands-clinical-research-network-into-arkansas-through-arkansas-renal-group-partnership"},{"publisher":"Naver","url":"https://n.news.naver.com/mnews/article/002/0002464630"}],"tags":["Partnerships","Dewpoint Therapeutics","Cancer Research UK"],"body_markdown":"Cancer Research UK will fund, sponsor and execute a first-in-human Phase 1/2a trial of [Dewpoint Therapeutics](https://akta.pro/company-profiles/00004aa/dewpoint-therapeutics)' DPTX8743, including CTA-enabling studies, the company said in a release covered by [TradingView](https://www.tradingview.com/news/tradingview:f46c0b0be9163:0-dewpoint-therapeutics-advances-dptx8743-to-a-funded-phase-1-2a-trial/). No agreement value or cost to Dewpoint was disclosed.\n\n## How the DPTX8743 Trial Will Run\n\nDPTX8743 is described as a potential first-in-class small molecule modulator of MYC condensates, aimed at a cancer driver the release calls historically undruggable. Cancer Research UK's Centre for Drug Development has agreed to fund, sponsor and execute the CTA-enabling studies and the Phase 1/2a trial. The collaboration is designed to evaluate safety and establish clinical proof of concept across MYC-driven cancers with high unmet need.\n\nDewpoint keeps all rights to DPTX8743 and may license the results and intellectual property. [Cancer Research UK](https://akta.pro/company-profiles/0005huh/cancer-research-uk) is eligible for downstream milestones and royalties; no amounts or specific milestones were disclosed. The release cites preclinical findings and no human results, and gives no timing or trial start date.\n\nCancer Research UK has backed a private member's bill requiring annual government reporting on cancer prevention, diagnosis and treatment, BBC reported on November 13, 2026, alongside 64 charities.\n\n## Dewpoint's Earlier Pipeline Steps\n\nDewpoint selected its first-in-class MYC condensate modulator development candidate in February 2026, according to akta.pro [company records](https://akta.pro/company-data), extending its oncology pipeline beyond Wnt-driven cancers. The same records show Dewpoint dosed the first patient in a Phase 1a/2a trial of DPTX3186 for advanced Wnt-pathway activated solid tumors, focused on gastric cancer, in February 2026. The records list a Series D financing of $77.2 million in September 2025 and total funding of $367.6 million.\n\n## Trial Partnerships Elsewhere\n\nNAMSA and Advanced Medical Solutions announced a preferred partnership on November 9, 2026, consolidating NAMSA's regulatory, testing and clinical services under one partner, [PR Newswire](https://www.prnewswire.com/news-releases/namsa-and-advanced-medical-solutions-announce-preferred-partnership-302932400.html) reported. Istios Health partnered with Arkansas Renal Group to expand its cardiovascular-kidney-metabolic clinical research network into Arkansas, [FinancialContent Business Page](https://www.financialcontent.com/article/gnwcq-2026-11-12-istios-health-expands-clinical-research-network-into-arkansas-through-arkansas-renal-group-partnership) reported on November 12, 2026. K-MedHub and the Korea Brain Research Institute signed a cooperation agreement on May 5, [Naver](https://n.news.naver.com/mnews/article/002/0002464630) reported on November 6, 2026, covering shared non-human primate facilities and joint national R&D planning.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}